Baker Ellis Asset Management’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $1.32M | Sell |
6,083
-40
| -0.7% | -$8.87K | 0.16% | 104 |
|
|
2025
Q4 | $1.4M | Sell |
6,123
-342
| -5% | -$77.9K | 0.17% | 99 |
|
|
2025
Q3 | $1.5M | Sell |
6,465
-78
| -1% | -$15.9K | 0.18% | 94 |
|
|
2025
Q2 | $1.21M | Sell |
6,543
-591
| -8% | -$110K | 0.17% | 95 |
|
|
2025
Q1 | $1.49M | Sell |
7,134
-59
| -0.8% | -$11.5K | 0.22% | 85 |
|
|
2024
Q4 | $1.28M | Sell |
7,193
-150
| -2% | -$27.6K | 0.19% | 88 |
|
|
2024
Q3 | $1.45M | Buy |
7,343
+588
| +9% | +$110K | 0.21% | 85 |
|
|
2024
Q2 | $1.16M | Hold |
6,755
| – | – | 0.17% | 97 |
|
|
2024
Q1 | $1.23M | Sell |
6,755
-490
| -7% | -$84.4K | 0.18% | 100 |
|
|
2023
Q4 | $1.12M | Buy |
7,245
+12
| +0.2% | +$1.75K | 0.18% | 101 |
|
|
2023
Q3 | $1.08M | Sell |
7,233
-616
| -8% | -$90.4K | 0.19% | 95 |
|
|
2023
Q2 | $1.06M | Sell |
7,849
-400
| -5% | -$58.7K | 0.18% | 97 |
|
|
2023
Q1 | $1.31M | Sell |
8,249
-100
| -1% | -$15.3K | 0.24% | 85 |
|
|
2022
Q4 | $1.35M | Sell |
8,349
-204
| -2% | -$31.3K | 0.26% | 79 |
|
|
2022
Q3 | $1.15M | Buy |
8,553
+130
| +2% | +$18.7K | 0.25% | 82 |
|
|
2022
Q2 | $1.29M | Buy |
8,423
+404
| +5% | +$61.7K | 0.27% | 78 |
|
|
2022
Q1 | $1.3M | Hold |
8,019
| – | – | 0.23% | 86 |
|
|
2021
Q4 | $1.09M | Hold |
8,019
| – | – | 0.19% | 96 |
|
|
2021
Q3 | $871K | Buy |
8,019
+390
| +5% | +$44.6K | 0.17% | 103 |
|
|
2021
Q2 | $859K | Sell |
7,629
-100
| -1% | -$11.3K | 0.17% | 98 |
|
|
2021
Q1 | $836K | Sell |
7,729
-175
| -2% | -$18.7K | 0.18% | 97 |
|
|
2020
Q4 | $847K | Sell |
7,904
-90
| -1% | -$8.65K | 0.2% | 92 |
|
|
2020
Q3 | $700K | Sell |
7,994
-125
| -2% | -$11.8K | 0.2% | 96 |
|
|
2020
Q2 | $797K | Hold |
8,119
| – | – | 0.24% | 95 |
|
|
2020
Q1 | $619K | Hold |
8,119
| – | – | 0.22% | 89 |
|
|
2019
Q4 | $719K | Sell |
8,119
-12,547
| -61% | -$1.04M | 0.2% | 90 |
|
|
2019
Q3 | $1.56M | Sell |
20,666
-550
| -3% | -$37.7K | 0.42% | 69 |
|
|
2019
Q2 | $1.54M | Sell |
21,216
-300
| -1% | -$23.6K | 0.41% | 68 |
|
|
2019
Q1 | $1.73M | Sell |
21,516
-450
| -2% | -$36.8K | 0.48% | 62 |
|
|
2018
Q4 | $2.02M | Sell |
21,966
-1,386
| -6% | -$122K | 0.61% | 45 |
|
|
2018
Q3 | $2.21M | Buy |
23,352
+500
| +2% | +$47.4K | 0.57% | 50 |
|
|
2018
Q2 | $2.12M | Sell |
22,852
-250
| -1% | -$24.4K | 0.56% | 51 |
|
|
2018
Q1 | $2.19M | Sell |
23,102
-1,250
| -5% | -$137K | 0.57% | 48 |
|
|
2017
Q4 | $2.35M | Sell |
24,352
-730
| -3% | -$68.8K | 0.59% | 48 |
|
|
2017
Q3 | $2.23M | Hold |
25,082
| – | – | 0.59% | 45 |
|
|
2017
Q2 | $1.82M | Sell |
25,082
-250
| -1% | -$16.8K | 0.5% | 60 |
|
|
2017
Q1 | $1.65M | Buy |
25,332
+220
| +0.9% | +$13.8K | 0.47% | 58 |
|
|
2016
Q4 | $1.57M | Sell |
25,112
-800
| -3% | -$48.8K | 0.46% | 64 |
|
|
2016
Q3 | $1.63M | Sell |
25,912
-300
| -1% | -$19.4K | 0.49% | 61 |
|
|
2016
Q2 | $1.62M | Sell |
26,212
-450
| -2% | -$27.4K | 0.51% | 57 |
|
|
2016
Q1 | $1.52M | Sell |
26,662
-233
| -0.9% | -$13K | 0.5% | 57 |
|
|
2015
Q4 | $1.59M | Buy |
26,895
+70
| +0.3% | +$4.03K | 0.55% | 49 |
|
|
2015
Q3 | $1.46M | Sell |
26,825
-37
| -0.1% | -$2.41K | 0.52% | 56 |
|
|
2015
Q2 | $1.8M | Sell |
26,862
-20
| -0.1% | -$1.31K | 0.61% | 45 |
|
|
2015
Q1 | $1.57M | Buy |
26,882
+1,000
| +4% | +$60.4K | 0.5% | 54 |
|
|
2014
Q4 | $1.69M | Sell |
25,882
-50
| -0.2% | -$3.15K | 0.57% | 48 |
|
|
2014
Q3 | $1.5M | Sell |
25,932
-150
| -0.6% | -$8.33K | 0.52% | 53 |
|
|
2014
Q2 | $1.47M | Sell |
26,082
-184
| -0.7% | -$9.65K | 0.5% | 57 |
|
|
2014
Q1 | $1.35M | Sell |
26,266
-600
| -2% | -$30.3K | 0.47% | 60 |
|
|
2013
Q4 | $1.42M | Sell |
26,866
-11,526
| -30% | -$566K | 0.49% | 54 |
|
|
2013
Q3 | $1.72M | Sell |
38,392
-2,598
| -6% | -$115K | 0.65% | 41 |
|
|
2013
Q2 | $1.7M | Buy |
+40,990
| New | +$1.79M | 0.67% | 39 |
|
Other funds holding ABBV
VCM
VPM
Baker Ellis Asset Management's ABBV Position: Q1 2026 in Review
Baker Ellis Asset Management reduced its AbbVie (ABBV) stake by 0.65% in Q1 2026, selling an estimated $8.87K and leaving 6,083 shares worth $1.32M. The position accounts for 0.16% of the portfolio, ranked #104.
Baker Ellis Asset Management first reported a position in ABBV in Q2 2013 and has held it in 52 quarters since. The position peaked at $2.35M in Q4 2017. 4,075 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.
- Baker Ellis Asset Management held 6,083 shares of AbbVie worth $1.32M as of Q1 2026.
- Baker Ellis Asset Management sold 40 AbbVie shares in Q1 2026, an estimated $8.87K.
- AbbVie made up 0.16% of Baker Ellis Asset Management's portfolio in Q1 2026, its #104 holding.
- Baker Ellis Asset Management first reported a position in AbbVie in Q2 2013 and has held it in 52 quarters since.
- Baker Ellis Asset Management's AbbVie position peaked at $2.35M in Q4 2017.
- 4,075 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.
Based on Baker Ellis Asset Management's 13F filing for Q1 2026, filed 17 Apr 2026.